Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MGTX
MGTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MGTX News
MeiraGTx Prices $100M Equity Offering to Acquire Gene Therapy bota-vec
4d ago
seekingalpha
MeiraGTx Acquires bota-vec from J&J for XLRP Treatment
4d ago
Newsfilter
MeiraGTx Shares Surge 17% to 52-Week High Ahead of Gene Therapy Data Presentation
5d ago
seekingalpha
MeiraGTx Presents 3-Year Data from AQUAx Clinical Study
6d ago
Newsfilter
MeiraGTx Stock Rises After Financial Results Announcement
Mar 26 2026
NASDAQ.COM
MeiraGTx Receives FDA Breakthrough Therapy Designation for AAV2-hAQP1
Mar 26 2026
Newsfilter
Strategic Shift in Biotech Dealmaking
Feb 17 2026
Globenewswire
Strategic Shift in Biopharma Dealmaking
Feb 17 2026
Newsfilter
Eli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy
Nov 10 2025
Benzinga
Eli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders
Nov 10 2025
SeekingAlpha
Raymond James Begins Coverage of MeiraGTx Holdings with Strong Buy Rating and Sets Price Target at $29
Oct 21 2025
Benzinga
Insider Sale: CFO & COO of $MGTX Sells 24,000 Shares
Jul 23 2025
NASDAQ.COM
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
May 14 2025
Benzinga
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Lowers Price Target to $35
May 14 2025
Benzinga
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13 2025
Newsfilter
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
May 09 2025
Newsfilter
Show More News
